Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 349 participants.

Also called NCT01941836

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 349 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01941836
Other papers using this trial's data
  • Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance Journal of clinical lipidology, 2016 DOI, PubMed 27206943

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01941836. Randomized; quadruple masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2014-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
Condition
Hypercholesterolemia
Intervention (Drug)
ETC-1002
Intervention (Drug)
Ezetimibe
Lead sponsor
Esperion Therapeutics, Inc. (class: industry)
Collaborator
Medpace, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01941836
Content hash
45a13c73853d43539ea14773049c2acaafbbb9c7a53f1396ef234ddacecadcee